These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18508951)

  • 1. Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus.
    Wang Y; Yin OQ; Graf P; Kisicki JC; Schran H
    J Clin Pharmacol; 2008 Jun; 48(6):763-75. PubMed ID: 18508951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.
    Yin OQ; Wang Y; Schran H
    Clin Pharmacokinet; 2008; 47(12):807-16. PubMed ID: 19026036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
    He H; Tran P; Gu H; Tedesco V; Zhang J; Lin W; Gatlik E; Klein K; Heimbach T
    Drug Metab Dispos; 2017 May; 45(5):540-555. PubMed ID: 28270565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
    Propper DJ; McDonald AC; Man A; Thavasu P; Balkwill F; Braybrooke JP; Caponigro F; Graf P; Dutreix C; Blackie R; Kaye SB; Ganesan TS; Talbot DC; Harris AL; Twelves C
    J Clin Oncol; 2001 Mar; 19(5):1485-92. PubMed ID: 11230495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
    Zhu Y; Statkevich P; Cutler DL
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
    Peter B; Winter GE; Blatt K; Bennett KL; Stefanzl G; Rix U; Eisenwort G; Hadzijusufovic E; Gridling M; Dutreix C; Hoermann G; Schwaab J; Radia D; Roesel J; Manley PW; Reiter A; Superti-Furga G; Valent P
    Leukemia; 2016 Feb; 30(2):464-72. PubMed ID: 26349526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
    Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
    Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
    Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
    Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.